Key result
Nanomaterials, including nanoparticles and liposomes, offer unique physico-chemical properties for antiviral drug delivery across biological barriers to treat viral infections.
Why the study?
Viral infections remain a major cause of mortality with increasing drug resistance and viral replication, prompting research into nanotechnology for antiviral drug delivery across biological barriers.
Nanomaterials offer unique physico-chemical properties that can improve antiviral drug delivery across biological barriers.
Nanomaterials may advance antiviral delivery; leaves open clinical translation pending prospective trials.
Viral infections are a major global health problem, representing a significant cause of mortality with an unfavorable continuously amplified socio-economic impact. The increased drug resistance and constant viral replication have been the trigger for important studies regarding the use of nanotechnology in antiviral therapies. Nanomaterials offer unique physico-chemical properties that have linked benefits for drug delivery as ideal tools for viral treatment. Currently, different types of nanomaterials namely nanoparticles, liposomes, nanospheres, nanogels, nanosuspensions and nanoemulsions were studied either in vitro or in vivo for drug delivery of antiviral agents with prospects to be translated in clinical practice. This review highlights the drug delivery nanosystems incorporating the major antiviral classes and their transport across specific barriers at cellular and intracellular level. Important reflections on nanomedicines currently approved or undergoing investigations for the treatment of viral infections are also discussed. Finally, the authors present an overview on the requirements for the design of antiviral nanotherapeutics.
No takes yet. Share an insight, caveat, or question.
Cojocaru et al. (2020) conducted a review in Viral infections. Nanomaterials for antiviral drug delivery was evaluated. Nanomaterials, including nanoparticles and liposomes, offer unique physico-chemical properties for antiviral drug delivery across biological barriers to treat viral infections.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: